KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder

  • KemPharm Inc KMPH announced topline data from its exploratory Phase 1 trial confirming the relative cardiovascular effects and pharmacokinetics of serdexmethylphenidate (SDX) compared to Ritalin (racemic methylphenidate), a commonly prescribed CNS stimulant. 
  • SDX, KemPharm's proprietary prodrug of d-methylphenidate (d-MPH), is the sole active pharmaceutical ingredient (API) in KP1077, a potential treatment for idiopathic hypersomnia (IH), a rare sleep disorder.
  • Based on the data, KemPharm believes the initial dosing strengths for the planned Phase 2 trial of KP1077 will be well-tolerated while providing higher overall exposures to d-MPH compared to other methylphenidate products that are often used off-label as a treatment for IH. 
  • KemPharm expects to initiate a Phase 2 trial of KP1077 in patients with IH before year-end 2022 and the second trial in patients with narcolepsy in 2023.
  • Initial results from the Phase 1 cardiovascular safety trial of SDX demonstrated the potential for 'higher dose' formulations of SDX to be safe and well-tolerated. 
  • Price Action: KMPH shares are up 6.61% at $6.16 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!